Allergan, Inc.: Difference between revisions
Content deleted Content added
m revised some technical formatting in infobox |
updated financials in infobox from provided references |
||
| Line 14: | Line 14: | ||
| industry = [[Pharmaceutical company|Pharmaceuticals]] |
| industry = [[Pharmaceutical company|Pharmaceuticals]] |
||
| products = [[Botox]], [[Acular]], [[Acuvail]], [[Alocril]], [[Prevage]], [[Avage]], [[Tazorac]], [[Juvederm]], [[Lap-band]], [[Restasis]], [[Alphagan]], [[Ganfort]], [[Hydrafill]], [[Optive]] |
| products = [[Botox]], [[Acular]], [[Acuvail]], [[Alocril]], [[Prevage]], [[Avage]], [[Tazorac]], [[Juvederm]], [[Lap-band]], [[Restasis]], [[Alphagan]], [[Ganfort]], [[Hydrafill]], [[Optive]] |
||
| revenue = {{profit}} [[United States Dollar|US$]]5. |
| revenue = {{profit}} [[United States Dollar|US$]]5.8 Billion <small>(2012)</small><ref name=IncomeStatement/>{{rp|F-5}} |
||
| operating_income = {{profit}} [[United States Dollar|US$]]1. |
| operating_income = {{profit}} [[United States Dollar|US$]]1.6 Billion <small>(2012)</small><ref name=IncomeStatement/>{{rp|F-5}} |
||
| net_income = {{profit}} [[United States Dollar|US$]] |
| net_income = {{profit}} [[United States Dollar|US$]]1.1 Billion <small>(2012)</small><ref name=IncomeStatement/>{{rp|F-6}} |
||
| assets = {{increase}} [[United States dollar|US$]] |
| assets = {{increase}} [[United States dollar|US$]]9.2 Billion <small>(2012)</small><ref name=IncomeStatement/>{{rp|F-4}} |
||
| equity = {{increase}} [[United States dollar|US$]]5. |
| equity = {{increase}} [[United States dollar|US$]]5.9 Billion <small>(2012)</small><ref name=IncomeStatement/>{{rp|F-4}} |
||
| num_employees = 10,800<ref name=IncomeStatement/>{{rp|20}} (~2,000 in R&D)<ref name=IncomeStatement/>{{rp|8}} (2012) |
|||
| num_employees = 8,500 |
|||
| homepage = {{URL|allergan.com}} |
| homepage = {{URL|allergan.com}} |
||
}} |
}} |
||
| Line 78: | Line 78: | ||
{{Reflist|refs= |
{{Reflist|refs= |
||
<ref name=IncomeStatement> |
<ref name=IncomeStatement>{{cite web | url=http://agn.client.shareholder.com/secfiling.cfm?filingID=850693-13-2 | title=Annual Report | year=2012 | publisher=Allergan | series=[[Form 10-K]] | accessdate=January 5, 2014 }}</ref> |
||
}} |
}} |
||
Revision as of 13:02, 5 January 2014
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
| Allergan | |
| Company type | Public |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1948 |
| Headquarters | Irvine, California |
Key people | |
| Products | Botox, Acular, Acuvail, Alocril, Prevage, Avage, Tazorac, Juvederm, Lap-band, Restasis, Alphagan, Ganfort, Hydrafill, Optive |
| Revenue |  US$5.8 Billion (2012)[1]: F-5 |
| US$1.6 Billion (2012)[1]: F-5 | |
| US$1.1 Billion (2012)[1]: F-6 | |
| Total assets | US$9.2 Billion (2012)[1]: F-4 |
| Total equity | US$5.9 Billion (2012)[1]: F-4 |
Number of employees | 10,800[1]: 20 (~2,000 in R&D)[1]: 8 (2012) |
| Website | allergan |
Allergan, Inc., is a global specialty pharmaceutical company. Their product ranges include ophthalmic pharmaceuticals, dermatology products, and neurological products.
Profile
The company's most notable neurologic product is Botox, used around the world to treat a variety of debilitating disorders associated with muscle overactivity and also well-known—under the trade names Botox Cosmetic and Vistabel—for the treatment of facial lines.
Its most important manufacturing plants are in Waco, Texas; Westport, Ireland; and San Jose, Costa Rica.
On April 23, 2001, Allergan Inc. participated in annual meeting of the European Bank for Reconstruction and Development (London to Tues).[2]
Allergan is also a member of the American Legislative Exchange Council (ALEC).[3] They are the state corporate co-chair of Tennessee, a "Chairman" level sponsor of 2011 ALEC Annual Conference, and member of Louisiana Host Committee.[3]
Products
- NATRELLE: Breast Implants (Silicone and Saline)
- LAP-BAND: An adjustable gastric band, inserted laparoscopically (in most circumstances); a restrictive device implanted via bariatric surgery and designed for obese patients with a body mass index (BMI) of 40 or greater.
- ORBERA SYSTEM: An intragastric balloon, inserted endoscopically; designed to assist weight loss by partially filling the stomach and inducing satiety for overweight patients with a body mass index (BMI) of 27 or greater.
- LUMIGAN: anti-glaucoma medication containing the active ingredient bimatoprost.
- Alphagan P: anti-(glaucoma) medication containing the active ingredient (brimonidine)
- ACULAR
- ACULAR LS
- ACZONE: for Acne control
- Acuvail
- Pred Forte: 1% prednisolone acetate suspension for reducing swelling, redness, itching, and allergic reactions affecting the eye
- ZYMAR .3%
- Zymaxid .5%
- F M L (fluorometholone)
- Combigan: anti-(glaucoma) medication containing a combination of active ingredients (brimonidine) and (timolol)
- BOTOX: anti-spasm medication containing the active ingredient botulinum toxin.
- REFRESH: artificial tears containing carboxymethylcellulose
- CELLUVISC
- DRY EYE THERAPY
- Sensitive
- LACRI-LUBE
- LASTACAFT® (alcaftadine ophthalmic solution) 0.25%
- LIQUIGEL
- PLUS
- P.M.
- REDNESS RELIEF
- TEARS
- OPTIVE: most advanced retail dry-eye treatment
- RESTASIS: dry eye treatment containing cyclosporine.
- JUVEDERM: used cosmetically for wrinkles and fine lines
- TAZORAC: for severe acne and psoriasis
- LATISSE: used to lengthen and thicken eyelashes (attenuated version of Lumigan)
- OZURDEX: for BRVO and CRVO
- VIVITE: Complete Facial Line
- SKINMEDICA: Complete Facial Line
 |
Notes
- ^ a b c d e f g "Annual Report". Form 10-K. Allergan. 2012. Retrieved January 5, 2014.
- ^ "This Week".
- ^ a b "ALEC Corporations". sourcewatch.org.
